DME Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

DME Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$87.7M	Sell	2,910,729 -148,005	-5%	-$4.76M	2.75%	13
2025 Q4	$95.5M	Sell	3,058,734 -720,043	-19%	-$17.7M	3.35%	10
2025 Q3	$76.3M	Hold	3,778,777	–	–	3%	10
2025 Q2	$63.3M	Buy	3,778,777 +3,210,577	+565%	+$51.8M	2.72%	12
2025 Q1	$8.73M	Buy	568,200 +99,650	+21%	+$1.78M	0.44%	23
2024 Q4	$10.3M	Buy	468,550 +143,700	+44%	+$2.61M	0.53%	22
2024 Q3	$5.85M	Hold	324,850	–	–	0.24%	28
2024 Q2	$5.28M	Hold	324,850	–	–	0.26%	27
2024 Q1	$4.58M	Buy	+324,850	New	+$4.09M	0.21%	29

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DME Capital Management's TEVA Position: Q1 2026 in Review

DME Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 4.8% in Q1 2026, selling an estimated $4.76M and leaving 2,910,729 shares worth $87.7M. The position accounts for 2.75% of the portfolio, ranked #13.

DME Capital Management first reported a position in TEVA in Q1 2024 and has held it in 9 quarters since. The position peaked at $95.5M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

DME Capital Management held 2,910,729 shares of Teva Pharmaceuticals worth $87.7M as of Q1 2026.
DME Capital Management sold 148,005 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.76M.
Teva Pharmaceuticals made up 2.75% of DME Capital Management's portfolio in Q1 2026, its #13 holding.
DME Capital Management first reported a position in Teva Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
DME Capital Management's Teva Pharmaceuticals position peaked at $95.5M in Q4 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.